2026-08-07 コペンハーゲン大学（UCPH）
＜関連情報＞
- https://news.ku.dk/all_news/2026/08/staying-on-diabetes-medication-is-linked-to-fewer-heart-attacks-and-strokes/
- https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00207-3/fulltext
2型糖尿病における血糖降下療法の長期遵守と心血管リスク：全国規模のコホート研究 Long-term adherence to glucose-lowering therapy and cardiovascular risk in type 2 diabetes: a nationwide cohort study
Lise B. Nielsen ∙ Andreas Bartholdy ∙ Tri-Long Nguyen ∙ Majken K. Jensen ∙ Simon Rasmussen ∙ Marta Guasch-Ferré ∙ et al.
The Lancet Regional Health – Europe Published: July 30, 2026
DOI:https://doi.org/10.1016/j.lanepe.2026.101795
Summary
Background
Type 2 diabetes is a major risk factor for cardiovascular disease, and reducing this excess risk is a central goal of clinical management. Sustained adherence to glucose-lowering medication is considered a key component of this strategy. However, long-term patterns of medication-taking behavior in real-world settings, and their relationship with cardiovascular outcomes, remain insufficiently characterized.
Methods
We conducted a nationwide cohort study of Danish adults with newly diagnosed type 2 diabetes who initiated non-insulin glucose-lowering medication between 2005 and 2012. Medication adherence was estimated from pharmacy dispensing data, and group-based trajectory modeling was used to identify longitudinal adherence patterns. The primary outcome was a composite cardiovascular outcome including ischemic heart disease, stroke, or heart failure. Associations between adherence trajectories and cardiovascular outcomes over 10 years of follow-up were assessed with Cox proportional-hazards models.
Findings
Among 79,510 individuals with newly diagnosed type 2 diabetes (median age, 61 (IQR: 52–69); 57% men), we identified three long-term adherence trajectories defined by high (n = 32,912; 41%), intermediate (n = 25,822; 33%), and low (n = 20,776; 26%) adherence. During follow-up, 15,276 cardiovascular events occurred. Compared with the high-adherence group, adjusted hazard ratios for the composite cardiovascular outcome were 1.07 (95% CI, 1.03–1.12) and 1.27 (95% CI, 1.21–1.33) in the intermediate- and low-adherence groups, respectively. Participants with high adherence remained free of cardiovascular events for an average of 220 more days (95% CI, 204–237) over 10 years. Associations were largely driven by ischemic heart disease, with no significant associations for heart failure.
Interpretation
Long-term adherence to glucose-lowering medication was associated with lower cardiovascular rate and longer event-free survival time among individuals with newly diagnosed type 2 diabetes.
Funding
Novo Nordisk Foundation and the European Innovation Council.
